# Putative Cognitive Enhancer VU319

> **NCT03220295** · PHASE1 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 52 (actual)

## Conditions studied

- Cognitive Impairment

## Interventions

- **DRUG:** Single Dose of VU319
- **DRUG:** Single Dose Placebo
- **OTHER:** Fed State
- **OTHER:** Fasted State
- **DRUG:** Dose Escalation of VU319
- **DRUG:** Placebo Dose Escalation

## Key facts

- **NCT ID:** NCT03220295
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-28
- **Primary completion:** 2019-10-30
- **Final completion:** 2019-10-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220295, "Putative Cognitive Enhancer VU319". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03220295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*